Amylin Pharmaceuticals: Diabetes and Beyond Harvard Case Solution & Analysis

Ginger Graham, the CEO of Amylin Pharmaceuticals , joined the expectation of taking the company's touch drug, Symlin, to market and the firm. However, unforeseen regulatory challenges have placed the acceptance procedure in peril.

Graham must determine how to manage the company's limited resources while also finalizing another deal that's tremendous future potential. Graham understands that Amylin's instant success is dependent upon its being able to commercialize its products but its long-term success depends on replenishing its pipeline. Can the company do it?

PUBLICATION DATE: December 09, 2008 PRODUCT #: 809011-HCB-ENG

This is just an excerpt. This case is about INNOVATION & ENTREPRENEURSHIP

Amylin Pharmaceuticals: Diabetes and Beyond Case Solution Other Similar Case Solutions like

Amylin Pharmaceuticals: Diabetes and Beyond

Share This